Sugi Predict

Sugi Predict / Compounds / SCHEMBL3029708

SCHEMBL3029708

SCHEMBL3029708

O=C(O)N1CCO[C@@H](CO)C1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDK1 Q15118 10/20 0.61
▸ PIK3CA P42336 2/20 0.38
▸ PIK3CD O00329 1/20 0.38
▸ PIK3R2 O00459 1/20 0.38
▸ PIK3CB P42338 1/20 0.38
▸ PIK3CG P48736 1/20 0.38
▸ PIK3R5 Q8WYR1 1/20 0.38
▸ PIK3R3 Q92569 1/20 0.38
▸ ALOX5AP P20292 1/20 0.35
▸ FEN1 P39748 1/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ ADORA1 P30542 1/20 0.35
▸ SCN9A Q15858 1/20 0.34
▸ OPRM1 P35372 1/20 0.34
▸ OPRL1 P41146 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ LRRK2 Q5S007 1/20 0.33
▸ ABL1 P00519 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2934637 1.00 PDK1 (0.61) PDK1PIK3CAPIK3CDPIK3R2PIK3CB
SCHEMBL571075 1.00 PDK1 (0.61) PDK1PIK3CAPIK3CDPIK3R2PIK3CB
SCHEMBL26135916 0.89 PDK1 (0.63) PDK1PIK3CAPIK3CDPIK3R2PIK3CB
SCHEMBL16934686 0.89 PDK1 (0.63) PDK1PIK3CAPIK3CDPIK3R2PIK3CB
SCHEMBL1291211 0.89 PDK1 (0.63) PDK1PIK3CAPIK3CDPIK3R2PIK3CB
SCHEMBL28132263 0.86 PDK1 (0.62) PDK1PIK3CAPIK3CDPIK3R2PIK3CB
SCHEMBL28133029 0.86 PDK1 (0.62) PDK1PIK3CAPIK3CDPIK3R2PIK3CB
SCHEMBL27785370 0.86 PDK1 (0.62) PDK1PIK3CAPIK3CDPIK3R2PIK3CB
SCHEMBL4725489 0.85 PDK1 (0.45) PDK1PIK3CAPIK3CDPIK3R2PIK3CB
SCHEMBL26128380 0.85 PDK1 (0.45) PDK1PIK3CAPIK3CDPIK3R2PIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085066-A1 LEUCINE RICH REPEAT KINASE 2 (LRRK2) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS INC (US) 2026-03-26 — — US disclosed
WO-2025133334-A1 NOVEL VDAC1 INHIBITORS ABARCEO PHARMA AB (SE) 2025-06-26 — — WO disclosed
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-20240208972-A1 LRRK2 INHIBITORS AND USES THEREOF NEURON23, INC. 2024-06-27 — — US disclosed
CN-118234731-A RAS inhibitors 锐新医药公司 2024-06-21 — — CN disclosed
WO-2024108116-A1 LRRK2 INHIBITORS AND USES THEREOF NEURON23, INC. (US) 2024-05-23 — — WO disclosed
US-20240158405-A1 SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2024-05-16 — — US disclosed
CN-111989321-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2024-05-14 — — CN disclosed
CN-117986251-A 4H-pyrrolo [3,2-c ] pyridin-4-one compounds 拜耳股份有限公司 2024-05-07 — — CN disclosed
CN-117946100-A 4H-pyrrolo [3,2-c ] pyridin-4-one compounds 拜耳股份有限公司 2024-04-30 — — CN disclosed
US-20080249301-A1 Regioselective Process for Preparing Benzimidazole Thiophenes SMITHKLINE BEECHAM CORPORATION 2008-10-09 — — US disclosed
CN-101151259-A Heteroaryl urea derivatives useful for inhibition of CHKI ICOS CORP (US) 2008-03-26 — — CN disclosed
EP-1831164-A1 HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS AstraZeneca AB (SE) 2007-09-12 — — EP disclosed
US-7238691-B2 Piperidine derivatives and their use as modulators of chemokine (especially CCR3) activity ASTRAZENECA AB (SE) 2007-07-03 — — US disclosed
EP-1430050-B1 PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE (ESPECIALLY CCR3) ACTIVITY ASTRAZENECA AB (SE) 2006-08-02 — — EP disclosed
WO-2006067401-A1 HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS ASTRAZENECA AB (SE) 2006-06-29 — — WO disclosed
CN-1726216-A C-6 modified indazolylpyrrolotriazines BRISTOL MYERS SQUIBB CO (US) 2006-01-25 — — CN disclosed
US-20040242577-A1 Piperdine derivatives and their use as modulators of chemokine (especially ccr3) activity ASTRAZENECA AB (SE) 2004-12-02 — — US disclosed
EP-1430050-A1 PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE (ESPECIALLY CCR3) ACTIVITY AstraZeneca AB (SE) 2004-06-23 — — EP disclosed
WO-2003024962-A1 PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE (ESPECIALLY CCR3) ACTIVITY ASTRAZENECA AB (SE) 2003-03-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242577-A1 Piperdine derivatives and their use as modulators of chemokine (especially ccr3) activity CCR3, CCR1, CCR2 PDK1 4731/4885PIK3CA 4593/4885PIK3CD 4252/4885
US-20240158405-A1 SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE LRRK2, ADRM1, CRBN PDK1 1358/4885PIK3CA 1997/4885PIK3CD 1798/4885
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PDK1 504/4885PIK3CA 142/4885PIK3CD 321/4885
US-20240208972-A1 LRRK2 INHIBITORS AND USES THEREOF LRRK2, PINK1, PARK7 PDK1 491/4885PIK3CA 657/4885PIK3CD 684/4885
US-20080249301-A1 Regioselective Process for Preparing Benzimidazole Thiophenes CYP3A4, CYP2C19, CYP2B6 PDK1 1016/4885PIK3CA 962/4885PIK3CD 802/4885
US-20260085066-A1 LEUCINE RICH REPEAT KINASE 2 (LRRK2) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE LRRK2, PARK7, NEDD4 PDK1 1325/4885PIK3CA 2856/4885PIK3CD 2134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.